Taiho Pharmaceutical Company Limited

Banyu Pharmaceutical Co. Ltd

Mds K.k.

Taiho Pahrmaceutical Co., Ltd.

Tetsuya Sugimoto

Morihiro Mitsuya

Toshihiro Sakamoto

Fuyuki Yamamoto

Hiroshi Sootome

Hidekazu Takahashi

Yoshiyuki Sato

Hideya Komatani

Norio Masuko

Kaori Kamijo

Koji Ichikawa

Yoshikazu Iwasawa

Masaaki Hirose

Nobuhiko Kawanishi

Hiroshi Hirai

Hideki Kazuno

Satoshi Sunami

Hideki Kurihara

Hitomi Kondo

Mikako Kawamura

Takashi Hashihayata

Yu Kobayakawa

Kouta Masutani

Tomohiro Yamamoto

Takumitsu Machida

Naoki Egashira

Yu Onozaki

Toshiaki Tsujino

Akiko Watanabe

Kaori Kamijyo

An indazole compound represented by the following Formula (I) or a salt thereof: wherein X, R, R, ring A, L, L, L, and Rare as defined in this specification.

Indazole compound or salt thereof

The invention of the present application provides a compound represented by Formula (I) or a salt thereof, which exhibits an inhibitory activity against at least one kinase selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or a cell proliferation inhibiting effect and is useful as a prophylactic and/or therapeutic agent for diseases associated with the above-mentioned kinases, particularly cancer. [In the formula, Rrepresents a 4- to 6-membered monocyclic unsaturated heterocyclic group which has 1 to 3 hetero atoms independently selected from N, S and O and may have a substituent; Rrepresents a hydrogen atom or the like; R, R, and R, may be the same as or different from one another and independently represent a hydrogen atom or the like; Rrepresents a hydrogen atom or the like; Rand R, may be the same as or different from each other and independently represent a hydrogen atom or the like; Xand Xmay be the same as or different from each other and independently represent N or CR; Rrepresents a hydrogen atom or the like; and Xrepresents N or CH when the broken line () represents a single bond, and represents C when a broken line indicates a double bond, wherein at least one of Xor Xrepresents N.] 

5H-pyrrolo[2,3-D]pyrimidin-6(7H)-one derivative

A novel compound which has an excellent aurora A-selective inhibitory action and is useful as an orally administrable anticancer agent is provided. Also, a novel agent for potentiation of anti-tumor effect of microtubule agonists, which include a taxane anticancer agent, and a combination therapy are provided. A piperidine compound represented by a general formula (I) or a salt thereof: 

Piperidine compound or salt thereof

The present invention relates to a compound represented by the Formula [I]: Wherein:

Fused imidazole derivative

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein:

Substituted imidazole derivative

A quinoxalinone derivative of the formula (I): or a pharmaceutically acceptable salt or ester thereof, wherein; is, for example, the formula: 

Quinoxalinone derivatives

Growing community of inventors

Tsukuba, Japan

Tetsuya Sugimoto